<?xml version="1.0" encoding="UTF-8"?>
<author-notes>
 <fn fn-type="COI-statement" id="coi001">
  <p>
   <bold>Competing Interests: </bold>Dr. Dale is the inventor of certain technologies related to the development of group A streptococcal vaccines. The technology has been licensed from the University of Tennessee Research Foundation to Vaxent, LLC. Dr. Dale is the Chief Scientific Officer of Vaxent and is a member. More specifically, the vaccine used in this manuscript was the subject of a US Patent #6063386 entitled Recombinant Multivalent M Protein Vaccines, which has subsequently expired. Additional patents related to other similar vaccines have since been submitted or have issued in the US, Europe, and elsewhere. This does not alter our adherence to PLOS ONE policies on sharing data and materials without restrictions.
  </p>
 </fn>
 <fn fn-type="current-aff" id="currentaff001">
  <label>Â¤</label>
  <p>Current address: Department of Population Medicine and Diagnostic Sciences, Animal Health Diagnostic Center, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States of America</p>
 </fn>
 <corresp id="cor001">* E-mail: 
  <email>michael.chaussee@usd.edu</email>
 </corresp>
</author-notes>
